Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hormonal analysis Clear all
Terminated Phase 2 Interventional Results available

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

NCT00918385
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nilutamide, Dasatinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational

Proportion of Hysterectomy After Female Sterilization

NCT02532361
View directory record Official record
Conditions
Hysterectomy
Interventions
Hysteroscopic device placement including Essure (ESS305, BAY1454032), Tubal ligation
Device · Procedure
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
10,578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
New Jersey, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational Results available

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

NCT06151418
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Novel hormonal therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 5, 2026, 5:28 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

NCT06931340
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Androgen Therapy, Apalutamide, Docetaxel, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, PSMA PET Scan, Biospecimen Collection, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2039
U.S. locations
210
States / cities
Tucson, Arizona • Dublin, California • Fremont, California + 170 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

NCT01023061
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
abiraterone acetate, prednisone, leuprolide acetate, laboratory biomarker analysis, external beam radiation therapy, goserelin acetate
Drug · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 5, 2026, 5:28 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs

NCT01371045
View directory record Official record
Conditions
Acromegaly
Interventions
Oral Glucose Tolerance Test (OGTT)
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 5, 2026, 5:28 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

NCT00310180
View directory record Official record
Conditions
Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIB Breast Cancer AJCC v7
Interventions
Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen Citrate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years · Female only
Enrollment
10,273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1160
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 723 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 3 Interventional

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

NCT00005970
View directory record Official record
Conditions
Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions
Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Tamoxifen Citrate, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 5, 2026, 5:28 PM EDT
Recruiting Phase 4 Interventional

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

NCT05919329
View directory record Official record
Conditions
Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma
Interventions
Piflufolastat, PSMA PET/CT Scan, PSMA PET/MRI scan, Biospecimen Collection, Electronic Health Record Review
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer

NCT04978675
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Fluorine F 18 rhPSMA-7.3, Magnetic Resonance Imaging, Positron Emission Tomography
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 5, 2026, 5:28 PM EDT
Terminated No phase listed Observational

The Effect of Bariatric Surgery on Spermatogenesis

NCT03725696
View directory record Official record
Conditions
Bariatric Surgery Candidate, Sexual Function and Fertility Disorders
Interventions
Semen Analysis, Hormonal panel, RYGB Gastric Bypass, IIEF Survey
Diagnostic Test · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis

NCT04568980
View directory record Official record
Conditions
Cystic Fibrosis, Contraception
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
562 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Comparison of Two Internet Supported Natural Family Planning Methods

NCT00843336
View directory record Official record
Conditions
Pregnancy
Interventions
Electronic hormonal fertility monitoring, Self-monitoring
Behavioral
Lead sponsor
Marquette University
Other
Eligibility
18 Years to 42 Years
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 5, 2026, 5:28 PM EDT
Suspended Phase 1Phase 2 Interventional

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

NCT04071236
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
Interventions
Avelumab, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Questionnaire Administration, Radium Ra 223 Dichloride
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Duarte, California • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Terminated Phase 1 Interventional

Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

NCT00512668
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
leuprolide acetate, goserelin acetate, bicalutamide, nilutamide, flutamide, temsirolimus, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Sep 5, 2026, 5:28 PM EDT
Recruiting Phase 2 Interventional

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial

NCT06067269
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
Interventions
Apalutamide, Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Guided Stereotactic Body Radiation Therapy, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration
Drug · Procedure · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Withdrawn No phase listed Observational

Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor

NCT02734823
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Gastrointestinal Stromal Tumor, Premenopausal
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Questionnaire Administration, Ultrasonography
Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational

Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib

NCT00602433
View directory record Official record
Conditions
Advanced Nonsmall Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 5, 2026, 5:28 PM EDT
Recruiting Phase 2 Interventional

A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa

NCT07077902
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Topical roflumilast 0.3% foam
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Covington, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Chemotherapy-Induced Changes to Cognition and DNA in Breast Cancer Survivors

NCT00496613
View directory record Official record
Conditions
Breast Cancer, Long-Term Survivors
Interventions
Mini-Mental State Exam and Blood Draw
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2022
U.S. locations
3
States / cities
Commack, New York • New York, New York • Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 5, 2026, 5:28 PM EDT
Not listed No phase listed Observational

Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.

NCT00910884
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, therapeutic dietary intervention
Other · Procedure
Lead sponsor
Brabant Research
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Spokane Valley, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 5, 2026, 5:28 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

NCT04134260
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography, Hormone Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
348
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 259 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Active, not recruiting Not applicable Interventional

MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ

NCT02352883
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ
Interventions
Magnetic Resonance Imaging, Therapeutic Conventional Surgery, Therapeutic Surgical Procedure, Radiation Therapy, Endocrine Therapy, Quality-of-Life Assessment, Laboratory Biomarker Analysis, Cytology Specimen Collection Procedure
Procedure · Radiation · Drug + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Female only
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
76
States / cities
San Diego, California • San Marcos, California • Greenwich, Connecticut + 56 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Early Phase 1 Interventional

Mediators of Abnormal Reproductive Function in Obesity (MARO)

NCT01817400
View directory record Official record
Conditions
Infertility, Female, Obesity
Interventions
Microdialysis, Vascepa - Fish Oil, Aspirin, Pioglitazone
Other · Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 5, 2026, 5:28 PM EDT